Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn’s disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson’s disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Metrics to compare | VTYX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVTYXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | −2.3x | −0.5x | |
PEG Ratio | −0.03 | 0.01 | 0.00 | |
Price/Book | 0.7x | 2.2x | 2.6x | |
Price / LTM Sales | - | 1.6x | 3.3x | |
Upside (Analyst Target) | 394.1% | 123.5% | 43.4% | |
Fair Value Upside | Unlock | 19.8% | 7.1% | Unlock |